{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:31:08Z","timestamp":1788690668555,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40257-022-00684-1","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T05:02:40Z","timestamp":1651554160000},"page":"409-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Baricitinib: A Review in Moderate to Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"23","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"684_CR1","doi-asserted-by":"publisher","unstructured":"Boytsov NN, Gorritz M, Wang X, et al. The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study. J Dermatolog Treat. 2021. https:\/\/doi.org\/10.1080\/09546634.2021.1898530.","DOI":"10.1080\/09546634.2021.1898530"},{"issue":"5","key":"684_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"684_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ad.2019.11.002","volume":"111","author":"M Munera-Campos","year":"2020","unstructured":"Munera-Campos M, Carrascosa JM. Innovation in atopic dermatitis: from pathogenesis to treatment. Actas Dermosifiliogr (Engl Ed). 2020;111(3):205\u201321.","journal-title":"Actas Dermosifiliogr (Engl Ed)."},{"issue":"11","key":"684_CR4","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40265-020-01335-7","volume":"80","author":"M Newsom","year":"2020","unstructured":"Newsom M, Bashyam AM, Balogh EA, et al. New and emerging systemic treatments for atopic dermatitis. Drugs. 2020;80(11):1041\u201352.","journal-title":"Drugs"},{"issue":"6","key":"684_CR5","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"684_CR6","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/ced.14567","volume":"46","author":"AM Cartron","year":"2021","unstructured":"Cartron AM, Nguyen TH, Roh YS, et al. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. Clin Exp Dermatol. 2021;46(5):820\u20134.","journal-title":"Clin Exp Dermatol"},{"key":"684_CR7","unstructured":"Eli Lilly Nederland B.V. Olumiant (baricitinib) film-coated tablets: EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/. Accessed 14 Dec 2021."},{"issue":"7","key":"684_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","volume":"78","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama ZT, Scott LJ. Baricitinib: a review in rheumatoid arthritis. Drugs. 2018;78(7):761\u201372.","journal-title":"Drugs"},{"key":"684_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O'Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328.","journal-title":"Annu Rev Med"},{"issue":"9","key":"684_CR10","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298\u2013307.","journal-title":"J Immunol"},{"issue":"12","key":"684_CR11","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/jcph.354","volume":"54","author":"JG Shi","year":"2014","unstructured":"Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54(12):1354\u201361.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"684_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.anai.2019.10.008","volume":"124","author":"C Drislane","year":"2020","unstructured":"Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol. 2020;124(1):36\u201343.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"684_CR13","volume":"30","author":"BJ Nickoloff","year":"2021","unstructured":"Nickoloff BJ, Colvin SC, Sims JT, et al. Inhibitory effects of baricitinib on a human skin model of atopic dermatitis [abstract no. P103]. Exp Dermatol. 2021;30(3): e52.","journal-title":"Exp Dermatol"},{"issue":"8","key":"684_CR14","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/cpdd.868","volume":"9","author":"X Zhao","year":"2020","unstructured":"Zhao X, Sheng XY, Payne CD, et al. Pharmacokinetics, safety, and tolerability of single- and multiple-dose once-daily baricitinib in healthy Chinese subjects: a randomized placebo-controlled study. Clin Pharmacol Drug Dev. 2020;9(8):952\u201360.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"4","key":"684_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","volume":"80","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913-21.e9.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"684_CR16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355.","journal-title":"Br J Dermatol"},{"issue":"12","key":"684_CR17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333\u201343.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"684_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","volume":"157","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Simpson EL, Wollenberg A, et al. Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol. 2021;157(6):691\u20139.","journal-title":"JAMA Dermatol"},{"key":"684_CR19","unstructured":"Bieber T, Reich K, Paul C, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis who failed, are intolerant to, or have contraindication to cyclosporine: results from a randomized, placebo-controlled, phase 3 clinical trial (BREEZE-AD4) [abstract no. P0181]. In: 29th Congress of EADV. 2020."},{"issue":"1","key":"684_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","volume":"85","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85(1):62\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"684_CR21","unstructured":"Simpson E, Boguniewicz M, Finklea L, et al. Long-term efficacy of baricitinib 2-mg for the treatment of atopic dermatitis in North America [abstract no. 466 plus poster]. In: Revolutionizing Atopic Dermatitis Conference (RAD). 2021."},{"key":"684_CR22","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT03428100. 2021. https:\/\/clinicaltrials.gov\/. Accessed 10 Feb 2022."},{"key":"684_CR23","unstructured":"European Medicines Agency. Olumiant (baricitinib): EU variation assessment report. 2020. https:\/\/www.ema.europa.eu\/. Accessed 21 Feb 2022."},{"key":"684_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1839008","author":"K Reich","year":"2020","unstructured":"Reich K, DeLozier AM, Nunes FP, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat. 2020. https:\/\/doi.org\/10.1080\/09546634.2020.1839008.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"684_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s13555-021-00534-8","volume":"11","author":"T Buhl","year":"2021","unstructured":"Buhl T, Rosmarin D, Serra-Baldrich E, et al. Itch and sleep improvements with baricitinib in patients with atopic dermatitis: a post hoc analysis of 3 phase 3 studies. Dermatol Ther (Heidelb). 2021;11(3):971\u201382.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"7","key":"684_CR26","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/jdv.17278","volume":"35","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Nakahara T, Maari C, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 phase 3 randomized trial. J Eur Acad Dermatol Venereol. 2021;35(7):1543\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"684_CR27","unstructured":"Bieber T, Reich K, Paul C, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in moderate-to-severe atopic dermatitis patients with cyclosporine failure, intolerance, or contraindication: 52-week results from the BREEZE-AD 4 trial [abstract no. PT32]. Adv Dermatol Venereol. 2021;101(Suppl 221):63."},{"issue":"2","key":"684_CR28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"684_CR29","unstructured":"sanofi-aventis groupe. Dupixent (dupilumab) solution for injection: EU summary of product characteristics 2021. https:\/\/www.ema.europa.eu\/. Accessed 13 Dec 2021."},{"key":"684_CR30","unstructured":"Pfizer Europe MA EEIG. Cibinqo (abrocitinib) film-coated tablets: EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/. Accessed 11 Feb 2022."},{"key":"684_CR31","unstructured":"AbbVie Deutschland GmbH & Co. KG. RINVOQ (upadacitinib) prolonged-release tablets: EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/. Accessed 13 Dec 2021."},{"key":"684_CR32","unstructured":"LEO Pharma A\/S. Adtralza (tralokinumab) 150 mg solution for injection in pre-filled syringe: EU summary of product characteristics. 2021. https:\/\/www.ema.europa.eu\/. Accessed 13 Dec 2021."},{"key":"684_CR33","unstructured":"UK National Institute for Health Excellence. Dupilumab for treating moderate to severe atopic dermatitis: technology appraisal guidance (TA534). 2018. https:\/\/www.nice.org.uk\/guidance\/ta534. Accessed 15 Dec 2021."},{"key":"684_CR34","unstructured":"UK National Institute for Health Excellence. Baricitinib for treating moderate to severe atopic dermatitis: technology appraisal guidance (TA681). 2021. https:\/\/www.nice.org.uk\/guidance\/ta681. Accessed 21 Feb 2022."},{"key":"684_CR35","doi-asserted-by":"publisher","unstructured":"Melo A, Carrascosa JM, Torres T. Baricitinib for the treatment of atopic dermatitis. J Dermatolog Treat. 2021. https:\/\/doi.org\/10.1080\/09546634.2021.1967268.","DOI":"10.1080\/09546634.2021.1967268"},{"key":"684_CR36","unstructured":"De Bruin-Weller M, Serra-Baldrich E, Barbarot S, et al. Indirect treatment comparison of baricitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis [abstract]. In: 16th EADV Symposium. 2021."},{"key":"684_CR37","doi-asserted-by":"crossref","unstructured":"Reich K, Simpson E, Wollenberg A, et al. Efficacy with continuous dosing, down-titration, or treatment withdrawal after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis [abstract no. 041]. J Invest Dermatol. 2021;141(10 Suppl 2):S155.","DOI":"10.1016\/j.jid.2021.08.043"},{"key":"684_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-021-01730-6","author":"M Akbarzadeh-Khiavi","year":"2021","unstructured":"Akbarzadeh-Khiavi M, Torabi M, Rahbarnia L, et al. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection. Infection. 2021. https:\/\/doi.org\/10.1007\/s15010-021-01730-6.","journal-title":"Infection"}],"updated-by":[{"DOI":"10.1007\/s40257-022-00717-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00684-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00684-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00684-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:03:38Z","timestamp":1670936618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00684-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00684-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"8 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-022-00717-9","URL":"https:\/\/doi.org\/10.1007\/s40257-022-00717-9","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sheridan Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}